Skip to content
Research Article Open access CC BY 4.0

Raltegravir in the Treatment of HIV–2 Infection: A Report of Eight Cases

Diana Póvoas, Sara Lino, Maria José Manata, João Machado, Fernando Maltez

International Journal of Medical and Pharmaceutical Case Reports · pp. 36–43 · Published 6 Oct 2014

10.9734/IJMPCR/2015/13078

Abstract

Background: Although endemic in West Africa, HIV-2 infection dissemination is limited to about 1.2 million people worldwide. However, the prevalence of HIV-2 infection is in Portugal disproportionately high, similarly to other countries with strong socioeconomic ties with West African former colonies. Due to HIV-2 intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (non-NRTIs) and enfuvirtide, along with reduced susceptibility to several of the protease inhibitors (PI), antiretroviral therapy (ART) relies on a regimen containing two NRTIs and a selected boosted PI. The integrase inhibitor raltegravir (RAL) showed, in vitro, activity against HIV-2 infection, and small case series published report RAL efficacy in the treatment of HIV-2 infection. Methods: We report eight HIV-2 ART-experienced patients treated with a RAL-containing regimen. Results: In this small series of eight patients, medium time of known HIV-2 infection before RAL introduction was 9.4 years; all had previous exposition to ART, some with more than 3 past therapeutic regimens. The majority had low CD4+T cell count. Despite these clinical aspects, the majority showed undetectable viral load (75%) and improvement or stability of the CD4+ T cell count (63%). Conclusion: Despite limitations inherent to this small case series, RAL proved to be useful in the treatment of HIV-2 infected patients, with beneficial effect in virus control and CD4+T cell preservation. In the presence of extensive resistance to other antiretrovirals, the benefit of RAL seems to be decreased. Accordingly to other emergent data, RAL may represent a novel therapeutic possibility for HIV-2 infected patients.

HIV-2 infection raltegravir RAL

References (29)

  1. 1 Slower heterosexual spread of HIV-2 than HIV-1 [DOI]
  2. 2 HIV-2: the forgotten AIDS virus [DOI]
  3. 3 Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates ofHIV-1 and HIV-2 in The Gambia [DOI]
  4. 4 Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? [DOI]
  5. 5 In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors [DOI]
  6. 6 Human Immunodeficiency Virus Type 2 Infection Associated with AIDS in West Africa [DOI]
  7. 7 Prospective Comparison of Mother-to-Child Transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast [DOI]
  8. 8 HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro [DOI]
  9. 9 Inhibition of HIV‐2 Protease by HIV‐1 Protease Inhibitors in Clinical Use [DOI]
  10. 10 Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2 [DOI]
  11. 11 Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic [DOI]
  12. 12 Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission [DOI]
  13. 13 Mother‐to‐Child Transmission of HIV‐2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF‐CO1 [DOI]
  14. 14 Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients [DOI]
  15. 15 Special Aspects of the Treatment of HIV-2-Infected Patients [DOI]
  16. 16 In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572 [DOI]
  17. 17 Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc [DOI]
  18. 18 Mutations selected in HIV-2-infected patients failing a regimen including atazanavir [DOI]
  19. 19 Raltegravir treatment response in an HIV-2 infected patient: a case report [DOI]
  20. 20 20 Years of HIV‐2 Infection in Portugal: Trends and Changes in Epidemiology [DOI]
  21. 21 Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen [DOI]
  22. 22 Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir [DOI]
  23. 23 An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHI E V 2E Quality Control Study [DOI]
  24. 24 HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa [DOI]
  25. 25 The Role of Raltegravir in the Treatment of HIV-2 Infections: Evidence from a Case Series [DOI]
  26. 26 Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau [DOI]
  27. 27 Profile of the HIV Epidemic in Cape Verde: Molecular Epidemiology and Drug Resistance Mutations among HIV-1 and HIV-2 Infected Patients from Distinct Islands of the Archipelago [DOI]
  28. 28 Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection [DOI]
  29. 29 HIV trends in African blood donors [DOI]

Cited by 3

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

the University of Washington-Dakar HIV-2 Study Group, Robert A Smith, Dana N Raugi · Retrovirology · 2015

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

30

Page views

0

PDF downloads

13

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.